The FDA completed the first-cycle review of an Abbreviated New Drug Application (ANDA) involving NRx Pharmaceuticals and Teva.

1 report, 1 independent Updated Aug 1

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Teva Pharmaceutical Industries Ltd.

Keep exploring

Part of

NRx Pharmaceuticals filed a petition with the FDA requesting the removal of the drug BZT. All 1 developments

The entities involved

FDA
- BridgeBio announced on August 14, 2026, that it has submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA).17:22
- Aidoc received FDA clearance for its medical AI solutions, which are developed by the company and co-founded by Elad Walach.16:57
Teva Pharmaceutical Industries Ltd.
Israeli pharmaceutical company

Nothing else this week.

Related events

FDA completed mid-cycle review of INO-3107, and Inovio Pharmaceuticals announced the appointment of EY as its independent registered public accounting firm.Jun 7

Coverage

Newest first; wire copies grouped

Aug 1manilatimes.net